Genetically engineered multivalent proteins for targeted immunotherapy

Research output: Contribution to journalArticle

2 Scopus citations


mAbs initiated the unprecedented breakthroughs in cancer immunotherapy and are rapidly evolving with multiple therapeutic platforms. One next-generation strategy engineers multivalent proteins that ligate single-chain variable fragments targeting cellular effectors, tumor-associated antigens, and cytokines. These developing therapeutics target and regulate cellular effector bioactivity and significantly improve clinical outcomes.

Original languageEnglish (US)
Pages (from-to)3419-3421
Number of pages3
JournalClinical Cancer Research
Issue number14
StatePublished - Jul 15 2016


ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this